Myriad Genetics, Inc. 2025 Q1 – Results – Earnings Call Presentation (NASDAQ:MYGN)

Q1: 2025-05-06 Earnings Summary EPS of -$0.03 beats by $0.02  | Revenue of $195.90M (-3.12% Y/Y) misses…

New pope will face a Vatican budget crisis, and a myriad other problems

New pope will face a Vatican budget crisis, and a myriad other problems#pope #face #Vatican #budget…

Myriad Genetics stock hits 52-week low at $9.36 amid challenges

Myriad Genetics stock hits 52-week low at $9.36 amid challenges#Myriad #Genetics #stock #hits #52week #challenges

New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries. By Investing.com

AUCKLAND, New Zealand, Jan. 16, 2025 /PRNewswire/ — New Zealand headquartered soft tissue regeneration company  Aroa…